Search Results

There are 164913 results for: content related to: Phase II Study of Weekly Docetaxel and Cisplatin in Patients With Advanced Recurrent and Metastatic Head and Neck Cancer

  1. You have full text access to this OnlineOpen article
    Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

    Cancer Science

    Volume 106, Issue 5, May 2015, Pages: 497–504, Hirotsugu Kenmotsu and Yusuke Tanigawara

    Version of Record online : 25 MAR 2015, DOI: 10.1111/cas.12647

  2. Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer

    Veterinary and Comparative Oncology

    Volume 12, Issue 2, June 2014, Pages: 160–168, A. Waite, C. Balkman, D. Bailey, M. Kiselow, A. Flory, B. B. Beaulieu, L. D. Lewis and M. McEntee

    Version of Record online : 21 AUG 2012, DOI: 10.1111/j.1476-5829.2012.00350.x

  3. Docetaxel-Associated Epiphora

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 6, June 2006, Pages: 853–867, Dr. Polly E. Kintzel, Dr. Laura B. Michaud and Dr. Marianne K. Lange

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.26.6.853

  4. Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution

    The Journal of Gene Medicine

    Volume 12, Issue 6, June 2010, Pages: 516–527, Xiong Li, Youhong Liu, Yong Tang, Phipps Roger, Meei-Huey Jeng and Chinghai Kao

    Version of Record online : 17 MAY 2010, DOI: 10.1002/jgm.1462

  5. You have free access to this content
    Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model

    International Journal of Cancer

    Volume 138, Issue 3, 1 February 2016, Pages: 758–769, Jeroen J.M.A. Hendrikx, Jurjen S. Lagas, Ji-Ying Song, Hilde Rosing, Jan H.M. Schellens, Jos H. Beijnen, Sven Rottenberg and Alfred H. Schinkel

    Version of Record online : 21 SEP 2015, DOI: 10.1002/ijc.29812

  6. Docetaxel Nanotechnology in Anticancer Therapy


    Volume 7, Issue 6, June 2012, Pages: 952–972, Pengxiang Zhao and Didier Astruc

    Version of Record online : 19 APR 2012, DOI: 10.1002/cmdc.201200052

  7. Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry

    Rapid Communications in Mass Spectrometry

    Volume 27, Issue 17, 15 September 2013, Pages: 1925–1934, J. J. M. A. Hendrikx, A. C. Dubbelman, H. Rosing, A. H. Schinkel, J. H. M. Schellens and J. H. Beijnen

    Version of Record online : 19 JUL 2013, DOI: 10.1002/rcm.6654

  8. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer

    The Prostate

    Volume 75, Issue 15, November 1, 2015, Pages: 1814–1820, Benjamin L. Maughan, Xian C. Xhou, Daniel L. Suzman, Rosa Nadal, Sunakshi Bassi, Michael T. Schweizer and Emmanuel S. Antonarakis

    Version of Record online : 26 AUG 2015, DOI: 10.1002/pros.23064

  9. You have free access to this content
    Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

    BJU International

    Volume 107, Issue 2, January 2011, Pages: 234–239, Giuseppe Di Lorenzo, Carlo Buonerba, Adriana Faiella, Pasquale Rescigno, Mimma Rizzo, Riccardo Autorino, Sisto Perdonà, Nando Riccardi, Sarah Scagliorini, Florinda Scognamiglio, Daniele Masala, Matteo Ferro, Giovannella Palmieri, Michele Aieta, Alfredo Marinelli, Vincenzo Altieri, Sabino De Placido and Giacomo Cartenì

    Version of Record online : 29 JUN 2010, DOI: 10.1111/j.1464-410X.2010.09498.x

  10. You have free access to this content
    A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer


    Volume 118, Issue 13, 1 July 2012, Pages: 3283–3293, Angeles Alvarez Secord, Andrew Berchuck, Robert V. Higgins, Lawrence R. Nycum, Matthew F. Kohler, Larry E. Puls, Robert W. Holloway, George S. Lewandowski, Fidel A. Valea and Laura J. Havrilesky

    Version of Record online : 9 NOV 2011, DOI: 10.1002/cncr.26610

  11. You have free access to this content
    Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer

    British Journal of Clinical Pharmacology

    Volume 69, Issue 5, May 2010, Pages: 465–474, Stijn L. W. Koolen, Roos L. Oostendorp, Jos H. Beijnen, Jan H. M. Schellens and Alwin D. R. Huitema

    Version of Record online : 28 JAN 2010, DOI: 10.1111/j.1365-2125.2010.03621.x

  12. Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity

    The Prostate

    Volume 72, Issue 6, 1 May 2012, Pages: 661–667, Peter Makhov, Konstantin Golovine, Daniel Canter, Alexander Kutikov, Jay Simhan, Melany M. Corlew, Robert G. Uzzo and Vladimir M. Kolenko

    Version of Record online : 27 JUL 2011, DOI: 10.1002/pros.21469

  13. Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study

    Diseases of the Esophagus

    Volume 27, Issue 8, November/December 2014, Pages: 737–743, T. Moriwaki, T. Kajiwara, T. Matsumoto, H. Suzuki, Y. Hiroshima, K. Matsuda, S. Hirai, Y. Yamamoto, T. Yamada, A. Sugaya, M. Kobayashi, S. Endo, K. Ishige, T. Nishina and I. Hyodo

    Version of Record online : 11 JUN 2014, DOI: 10.1111/dote.12246

  14. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer

    The Prostate

    Volume 70, Issue 13, 15 September 2010, Pages: 1437–1447, Alain G. Musende, Andy Eberding, William Jia, Euan Ramsay, Marcel B. Bally and Emma Tomlinson Guns

    Version of Record online : 28 APR 2010, DOI: 10.1002/pros.21179

  15. You have free access to this content
    Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

    BJU International

    Volume 106, Issue 7, October 2010, Pages: 974–978, Jean-Christophe Eymard, Stéphane Oudard, Gwenaelle Gravis, Jean-Marc Ferrero, Christine Theodore, Florence Joly, Frank Priou, Ivan Krakowski, Alain Zannetti, Laurence Thill and Philippe Beuzeboc

    Version of Record online : 14 SEP 2010, DOI: 10.1111/j.1464-410X.2010.09296.x

  16. Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations

    The Journal of Clinical Pharmacology

    Volume 57, Issue 2, February 2017, Pages: 275–279, Nour Al Faqeer, Ola Mashni, Rawan Dawoud, Asma Rumman, Esraa Hanoun and Lama Nazer

    Version of Record online : 23 AUG 2016, DOI: 10.1002/jcph.803

  17. You have free access to this content
    Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)

    BJU International

    Volume 116, Issue 1, July 2015, Pages: 17–29, Guru Sonpavde, Christopher G. Wang, Matthew D. Galsky, William K. Oh and Andrew J. Armstrong

    Version of Record online : 23 OCT 2014, DOI: 10.1111/bju.12867

  18. You have free access to this content
    Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer

    BJU International

    Volume 110, Issue 11b, December 2012, Pages: E635–E640, Matthias M. Heck, Mark Thalgott, Margitta Retz, Petra Wolf, Tobias Maurer, Roman Nawroth, Georgios Hatzichristodoulou, Jürgen E. Gschwend and Hubert Kübler

    Version of Record online : 13 AUG 2012, DOI: 10.1111/j.1464-410X.2012.11364.x

  19. Functional p53 determines docetaxel sensitivity in prostate cancer cells

    The Prostate

    Volume 73, Issue 4, March 2013, Pages: 418–427, Chengfei Liu, Yezi Zhu, Wei Lou, Nagalakshmi Nadiminty, Xinbin Chen, Qinghua Zhou, Xu Bao Shi, Ralph W. deVere White and Allen C. Gao

    Version of Record online : 19 SEP 2012, DOI: 10.1002/pros.22583

  20. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells

    Cell Biology International

    Volume 33, Issue 2, February 2009, Pages: 239–246, B. Karabulut, C. Erten, M.K. Gul, E. Cengiz, B. Karaca, Y. Kucukzeybek, G. Gorumlu, H. Atmaca, S. Uzunoglu, U.A. Sanli, Y. Baran and R. Uslu

    Version of Record online : 2 JAN 2013, DOI: 10.1016/j.cellbi.2008.11.011